Vaccine Therapy for Patients With Stage III Melanoma

CancerVax

Status and phase: Unknown; Phase 3

Conditions: Malignant Melanoma

Treatments: Biological: CancerVax vaccine (CANVAXIN)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00052130

JWCI-MC-3-001A

CV-MMAIT-3-001

Details and patient eligibility

About

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Must have Stage III melanoma
• Must have had all clinically-detectable disease surgically removed
• Cannot be taking any medications, or undergoing any therapies which compromise the functioning of your immune system (ie. Some corticosteroids, and certain types of radiation therapy)
• Cannot have HIV or Hepatitis A, B, or C

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind